Gilead director granted RSUs and stock options
Gilead Sciences director Anthony Welters reported equity awards rather than open-market trades.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Gilead Sciences director Anthony Welters reported equity awards rather than open-market trades. On April 30, 2026, he received 1,146 restricted stock units that each convert into one share of common stock and vested immediately. He was also granted 4,884 non-qualified stock options with a $130.84 exercise price, which fully vested on the grant date and are exercisable until April 30, 2036. Following the RSU grant, his direct common stock holdings totaled 12,894 shares.
Insider Trade Summary
Grant/Award: 6,030 shares
Grant/Award
2 txns
Insider
WELTERS ANTHONY
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-qualified Stock Option (Right to Buy) | 4,884 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 1,146 | $0.00 | $0.00 |
Holdings After Transaction:
Non-qualified Stock Option (Right to Buy) — 4,884 contracts (Direct);
Common Stock — 12,894 shares (Direct)
Footnotes (2)
- F1. Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.
- F2. 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.
Key Figures
RSU grant: 1,146 RSUs
Option grant size: 4,884 options
Option exercise price: $130.84 per share
+2 more
5 metrics
RSU grant
1,146 RSUs
Restricted stock units granted April 30, 2026; vested immediately
Option grant size
4,884 options
Non-qualified stock options granted April 30, 2026
Option exercise price
$130.84 per share
Exercise price for newly granted non-qualified stock options
Option expiration
April 30, 2036
Expiration date of non-qualified stock options
Shares held after grant
12,894 shares
Direct Gilead common stock holdings after RSU grant
Key Terms
restricted stock units, Non-qualified Stock Option, 2022 Equity Incentive Plan, exercise price, +1 more
5 terms
restricted stock units financial
"Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Non-qualified Stock Option financial
"Non-qualified Stock Option (Right to Buy) with an exercise price of 130.8400."
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
2022 Equity Incentive Plan financial
"RSUs granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."
exercise price financial
"conversion_or_exercise_price: "130.8400" for the stock option grant."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Form 4 regulatory
"INSIDER FILING DATA (Form 4): details the equity awards to Anthony Welters."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Gilead Sciences (GILD) director Anthony Welters report?
Anthony Welters reported equity compensation awards, not open-market trades. He received 1,146 restricted stock units and 4,884 non-qualified stock options on April 30, 2026, both granted under Gilead’s 2022 Equity Incentive Plan and vesting immediately on the grant date.
How many Gilead (GILD) restricted stock units did Anthony Welters receive?
Anthony Welters received 1,146 restricted stock units in Gilead stock. Each RSU represents the right to receive one share of Gilead common stock, and all RSUs vested immediately on April 30, 2026, providing him with fully vested stock-based compensation on the grant date.
What are the terms of Anthony Welters’ new Gilead (GILD) stock options?
Welters was granted 4,884 non-qualified stock options with a $130.84 exercise price. All of these options vested 100% on April 30, 2026, and are exercisable for Gilead common stock until April 30, 2036, giving him a long-dated equity incentive.
Under which plan were Anthony Welters’ new Gilead (GILD) awards granted?
The RSUs and stock options were granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. This plan provides equity-based compensation such as restricted stock units and stock options to directors and other eligible participants as part of their overall remuneration.
AI-generated analysis. How Rhea-AI works. Not financial advice.
